MedTrace Logo

Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

NCT00699712 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-03-25

No results posted yet for this study

Summary

To access the efficacy of intravenous (IV) administration of CD-NP on changes in cardiac output and wedge pressure in patients with stabilized acute heart failure

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

CD-NP (Chimeric natriuretic peptide)

Infusion of CDNP at two of four doses

Sponsors & Collaborators

  • Momentum Research, Inc.

    collaborator INDUSTRY

  • Nile Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hsiao Lieu, MD · Nile Therapeutics Inc.

  • Gad Cotter, MD · Momentum Research, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699712 on ClinicalTrials.gov